Abstract
Antiviral agents are urgently needed to fight severe acute respiratory syndrome (SARS). We showed that niclosamide, an existing antihelminthic drug, was able to inhibit replication of a newly discovered coronavirus, SARS-CoV; viral antigen synthesis was totally abolished at a niclosamide concentration of 1.56 μM, as revealed by immunoblot analysis. Thus, niclosamide represents a promising drug candidate for the effective treatment of SARS-CoV infection.
Original language | English |
---|---|
Pages (from-to) | 2693-2696 |
Number of pages | 4 |
Journal | Antimicrobial agents and chemotherapy |
Volume | 48 |
Issue number | 7 |
DOIs | |
Publication status | Published - 2004 Jul |
All Science Journal Classification (ASJC) codes
- Pharmacology
- Pharmacology (medical)
- Infectious Diseases